To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.
Despite advances in AMI treatment, a substantial proportion of patients develop LVAR, leading to heart failure and increased MACE risk. Conventional biomarkers (e.g., troponin, NT-proBNP) lack sufficient predictive power for adverse outcomes. Multi-omics approaches - integrating proteomics(e.g., exosome proteomics), metabolomics, transcriptomics and lipidomics - offer a systems-level view that may uncover novel prognostic signatures.
Study Type
OBSERVATIONAL
Enrollment
1,000
Blood samples were collected from all patients at the time of myocardial infarction (MI) diagnosis. For those with acute ST-elevation myocardial infarction, blood samples were taken on the day of diagnosis(T0), as well as two days (T1), one week (T2) and one month (T3) after percutaneous coronary intervention (PCI). Echocardiography was performed at the time of STEMI diagnosis, and then again at one week, one month, and six months post-onset.
Beijing Anzhen Hospital, Capital Medical University.
Beijing, Beijing Municipality, China
major adverse cardiovascular events
Identify T0 plasma multi-omics biomarkers that predict cardiac death, myocardial infarction, heart failure, and stroke.
Time frame: 2025-1-1 to 2027-12-31
adverse cardiac remodeling
To assess the predictive ability of multi-omics biomarkers in T0 plasma for adverse cardiac remodeling, and to identify new candidate markers for forecasting this condition.
Time frame: 2025-1-1 to 2027-12-31
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.